Annual SG&A
$23.45 M
+$5.83 M+33.05%
31 December 2023
Summary:
Edgewise Therapeutics annual selling, general & administrative expenses is currently $23.45 million, with the most recent change of +$5.83 million (+33.05%) on 31 December 2023. During the last 3 years, it has risen by +$12.43 million (+112.70%). EWTX annual SG&A is now at all-time high.EWTX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$8.21 M
+$783.00 K+10.54%
30 September 2024
Summary:
Edgewise Therapeutics quarterly selling, general & administrative expenses is currently $8.21 million, with the most recent change of +$783.00 thousand (+10.54%) on 30 September 2024. Over the past year, it has increased by +$2.03 million (+32.89%). EWTX quarterly SG&A is now at all-time high.EWTX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.16 B
-$124.29 M-11.98%
30 September 2024
Summary:
Edgewise Therapeutics TTM selling, general & administrative expenses is currently -$1.16 billion, with the most recent change of -$124.29 million (-11.98%) on 30 September 2024. Over the past year, it has dropped by -$1.19 billion (-5053.74%). EWTX TTM SG&A is now -3302.20% below its all-time high of $28.87 million, reached on 30 September 2024.EWTX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EWTX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +32.9% | -5053.7% |
| 3 y3 years | +112.7% | +119.9% | -10000.0% |
| 5 y5 years | +1704.0% | - | - |
EWTX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +112.7% | at high | +121.8% | -397.5% | at low |
| 5 y | 5 years | at high | +1704.0% | at high | +2821.7% | -3302.2% | at low |
| alltime | all time | at high | +1704.0% | at high | +2821.7% | -3302.2% | at low |
Edgewise Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $8.21 M(+10.5%) | $28.87 M(+9.7%) |
| June 2024 | - | $7.43 M(+5.2%) | $26.33 M(+6.7%) |
| Mar 2024 | - | $7.06 M(+14.3%) | $24.68 M(+5.2%) |
| Dec 2023 | $23.45 M(+33.1%) | $6.18 M(+9.0%) | $23.45 M(+3.1%) |
| Sept 2023 | - | $5.67 M(-2.0%) | $22.74 M(+6.1%) |
| June 2023 | - | $5.78 M(-0.8%) | $21.44 M(+8.6%) |
| Mar 2023 | - | $5.83 M(+6.6%) | $19.75 M(+12.1%) |
| Dec 2022 | $17.63 M | $5.47 M(+25.2%) | $17.63 M(+10.9%) |
| Sept 2022 | - | $4.37 M(+6.8%) | $15.89 M(+8.0%) |
| June 2022 | - | $4.09 M(+10.5%) | $14.72 M(+11.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $3.70 M(-0.9%) | $13.23 M(+20.0%) |
| Dec 2021 | $11.03 M(+399.1%) | $3.73 M(+16.8%) | $11.03 M(+29.8%) |
| Sept 2021 | - | $3.20 M(+23.0%) | $8.50 M(+48.9%) |
| June 2021 | - | $2.60 M(+73.6%) | $5.71 M(+66.6%) |
| Mar 2021 | - | $1.50 M(+24.2%) | $3.42 M(+55.0%) |
| Dec 2020 | $2.21 M(+69.9%) | $1.21 M(+197.5%) | $2.21 M(+120.0%) |
| Sept 2020 | - | $405.00 K(+27.4%) | $1.00 M(+67.6%) |
| June 2020 | - | $318.00 K(+13.2%) | $599.00 K(+113.2%) |
| Mar 2020 | - | $281.00 K | $281.00 K |
| Dec 2019 | $1.30 M | - | - |
FAQ
- What is Edgewise Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Edgewise Therapeutics?
- What is Edgewise Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Edgewise Therapeutics?
- What is Edgewise Therapeutics quarterly SG&A year-on-year change?
- What is Edgewise Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Edgewise Therapeutics?
- What is Edgewise Therapeutics TTM SG&A year-on-year change?
What is Edgewise Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of EWTX is $23.45 M
What is the all time high annual SG&A for Edgewise Therapeutics?
Edgewise Therapeutics all-time high annual selling, general & administrative expenses is $23.45 M
What is Edgewise Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of EWTX is $8.21 M
What is the all time high quarterly SG&A for Edgewise Therapeutics?
Edgewise Therapeutics all-time high quarterly selling, general & administrative expenses is $8.21 M
What is Edgewise Therapeutics quarterly SG&A year-on-year change?
Over the past year, EWTX quarterly selling, general & administrative expenses has changed by +$2.03 M (+32.89%)
What is Edgewise Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of EWTX is -$1.16 B
What is the all time high TTM SG&A for Edgewise Therapeutics?
Edgewise Therapeutics all-time high TTM selling, general & administrative expenses is $28.87 M
What is Edgewise Therapeutics TTM SG&A year-on-year change?
Over the past year, EWTX TTM selling, general & administrative expenses has changed by -$1.19 B (-5053.74%)